<code id='93C27D6BE2'></code><style id='93C27D6BE2'></style>
    • <acronym id='93C27D6BE2'></acronym>
      <center id='93C27D6BE2'><center id='93C27D6BE2'><tfoot id='93C27D6BE2'></tfoot></center><abbr id='93C27D6BE2'><dir id='93C27D6BE2'><tfoot id='93C27D6BE2'></tfoot><noframes id='93C27D6BE2'>

    • <optgroup id='93C27D6BE2'><strike id='93C27D6BE2'><sup id='93C27D6BE2'></sup></strike><code id='93C27D6BE2'></code></optgroup>
        1. <b id='93C27D6BE2'><label id='93C27D6BE2'><select id='93C27D6BE2'><dt id='93C27D6BE2'><span id='93C27D6BE2'></span></dt></select></label></b><u id='93C27D6BE2'></u>
          <i id='93C27D6BE2'><strike id='93C27D6BE2'><tt id='93C27D6BE2'><pre id='93C27D6BE2'></pre></tt></strike></i>

          Home / entertainment / leisure time

          leisure time


          leisure time

          author:leisure time    Page View:45498
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In